ETS1 and Behcet disease: Studies on miRNA155 expression levels in active BD disease should be done on a large base to know if there is a cut off to say the disease is active or in remission and for confirmation of the possibility of its usage as a biomarker for follow up of the patient, and to do studies for Ets-1 enhancement or other means of miRNA155 promotion to see the effect on disease progression and potential of this for disease treatment.